IMAB - I-Mab: Trading Below Net Cash With Multiple Upside Options
2024-02-18 03:28:21 ET
Summary
- I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company.
- The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive up to $80 million in cash consideration from its divested China operation.
- I-Mab's core assets will consist of three global Immuno-Oncology programs, including uliledlimab, which has shown promising Phase 2 NSCLC clinical trial data.
...
I-Mab: Trading Below Net Cash With Multiple Upside Options